Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
GeneDx (Nasdaq: WGS) reported preliminary, unaudited results for 2025 and issued 2026 guidance. Management expects 2025 revenue of $427M (+41% YoY) and exome & genome revenue of $360M (+54% YoY). Exome & genome volume rose to 97,271 results (+30.5%) with Q4 volume growth accelerating to 34.3%. full-year adjusted gross margin is ~71% and Q4 adjusted gross margin ~71%. Cash and equivalents were about $172M at year-end. For 2026 the company guides $540–$555M revenue, 33–35% exome & genome revenue and volume growth, adjusted gross margin at least 70%, and positive adjusted net income. Results remain subject to audit and adjustment.
GeneDx (Nasdaq: WGS) announced a strategic partnership with Komodo Health to link GeneDx Infinity’s rare disease genomic and phenotypic dataset with Komodo’s Healthcare Map®, creating a longitudinal rare disease dataset. The combined resource connects >2.5 million genetic tests, >7 million phenotypic data points, and Komodo’s view of >330 million de-identified patient journeys to support HEOR, R&D, clinical trial cohort ID, market access, and AI model training.
GeneDx reports Infinity produced 30% more exome/genome data in 2025 than the prior 24 years combined and includes nearly 1 million exomes/genomes and ~1 million uniquely classified variants.
GeneDx (Nasdaq: WGS) announced GenomeDx Prenatal, a phenotype-informed, trio whole genome sequencing test for pregnancies with fetal anomalies, available to order in February 2026. The test builds on >10 years of prenatal experience and >4,000 prenatal exomes, uses the GeneDx Infinity rare-disease dataset, and targets broad variant detection across key prenatal indications with results in less than two weeks. GenomeDx Prenatal is positioned to inform time-sensitive counseling, delivery planning, and postnatal care through comprehensive detection, free postnatal reanalysis, and optional lifetime reanalysis.
GeneDx (Nasdaq: WGS) appointed Dr. Linda Genen, MD, MPH as Chief Medical Officer on January 6, 2026 to lead Medical and Clinical Affairs and drive clinical strategy for earlier diagnosis and broader adoption of genomic medicine.
Dr. Genen joins from ProgenyHealth and has prior leadership at UnitedHealth Group, Optum, and clinical experience as a neonatologist and assistant professor. She will guide payer engagement, real-world evidence initiatives, and cross‑functional innovation to expand exome and genome testing in routine care.
GeneDx (Nasdaq: WGS) reported a record 2025 for medical affairs and research, publishing 79 peer-reviewed studies and reaching a cumulative total of over 1,100 studies. GeneDx says its GeneDx Infinity dataset includes nearly 1 million exomes and genomes with deep phenotypes and 25+ years of clinical experience. 2025 highlights include four practice‑shaping publications, 56 GeneMatcher-enabled discoveries, 38 conference abstracts, and the GUARDIAN newborn-screening study selected for JAMA’s Research of the Year Roundup. Reported outcomes: partnerships with 175 clinicians at 74 institutions, diagnoses for 136 patients, and 31 newly clinically validated gene–disease associations in 2025.
GeneDx (Nasdaq: WGS) announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–15, 2026. Katherine Stueland, President and CEO, will present on Wednesday, January 14, 2026 at 3:00 p.m. PT. Live and archived webcasts will be available in the company’s Events section on the investor relations website.
GeneDx (Nasdaq: WGS) announced the GUARDIAN newborn genomic screening study was named to JAMA’s Research of the Year roundup on December 15, 2025. The peer-reviewed analysis of the first 4,000 enrolled newborns reported a 72% parental consent rate, a 3.7% screen-positive rate, and that 92% of screen-positive newborns had a confirmed diagnosis for a condition not included in traditional newborn screening.
The study has screened more than 20,000 newborns to date with a goal of 100,000, and identifies actionable conditions (eg, long QT syndrome, Wilson disease, SCID) where earlier diagnosis enables timely intervention.
GeneDx (Nasdaq: WGS) will present research at the NSGC 2025 Annual Meeting (Nov 7–9, 2025) highlighting gene-disease discovery, long-read sequencing, and access/reimbursement work.
Key points: GeneDx promotes its GeneDx Infinity rare-disease dataset and cites >1,000 scientific publications. The company reports curation of >9,000 gene-disease associations and will present data showing HiFi long-read sequencing detected nearly all technically challenging variants and enabled phasing in singleton clinical samples.
GeneDx (Nasdaq: WGS) announced management will participate in three investor conferences in November–December 2025: a Stifel fireside chat on Nov 12, 2025 at 2:00 p.m. ET; a Jefferies presentation on Nov 19, 2025 at 11:00 a.m. GMT; and a Piper Sandler fireside chat on Dec 3, 2025 at 1:30 p.m. ET.
Live and archived webcasts will be available in the Events section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
GeneDx (Nasdaq: WGS) reported third quarter 2025 results with $116.7M revenue and year-over-year exome/genome revenue growth of 65%. Exome/genome volume rose to 25,702 (+33% YoY) and represented 43% of all tests. Adjusted gross margin expanded to 74% (from 64%), and adjusted net income was $14.7M versus $2.0M a year earlier. GAAP net loss was $7.6M. Cash and equivalents totaled $156.1M; free cash flow for the quarter was $8.8M. Management raised 2025 revenue guidance to $425–$428M and increased expected exome/genome revenue growth to 53%–55%. The company received FDA Breakthrough Device Designation for ExomeDx and GenomeDx and highlighted expanded genomic newborn screening participation.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
